The Journal of pediatrics · 2026
Prevalence and Treatment of US Children with Congenital Heart Disease and ADHD: A National Survey Analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fawcett Jenna, Zhang Xiao, Bommersbach Tanner, Munjal Neil, Olson Krisjon, Anderson Jesse Boyett
Аннотация
OBJECTIVE: To evaluate the intersection of congenital heart disease CHD and attention-deficit/hyperactivity disorder (ADHD,) in children we analyzed population-level data from the National Survey of Children's Health (NSCH).
STUDY DESIGN: We pooled 2020-2023 NSCH data for children aged 3-17 years old (N = 169,584) with and without parent-reported CHD and compared ADHD prevalence between these groups. Multivariable regression models assessed social and demographic risk factors for ADHD in children with and without CHD.
RESULTS: After multivariable correction, children with CHD had significantly higher prevalence of parent-reported ADHD than those without CHD (18.4% vs 10.7%, P < 0.05), with age-specific prevalence of 1.8% (ages 3-5), 13.1% (ages 6-8), 26.8% (ages 9-11), 25.5% (ages 12-14), and 25.0% (ages 15-17), with no significant differences across survey years. In weighted multivariable logistic regression, older age, male sex, prematurity, poorer parent-reported child health status, and foregone healthcare were associated with higher odds of ADHD in children with and without CHD (P < 0.05). Children with current CHD received treatment for ADHD with medication (44.5%) and behavioral intervention (46.2%) at similar prevalence to children without CHD (50.7% and 42.2%, respectively).
CONCLUSIONS: Children with CHD had higher parent-reported ADHD prevalence than peers without CHD, including nearly one in three adolescents aged 12-14. Children with CHD received ADHD treatments at prevalence comparable with those without CHD. Although limited by parent report and survey specificity, these national estimates highlight elevated ADHD prevalence in children with CHD and support strengthened neurodevelopmental surveillance guidelines.
STUDY DESIGN: We pooled 2020-2023 NSCH data for children aged 3-17 years old (N = 169,584) with and without parent-reported CHD and compared ADHD prevalence between these groups. Multivariable regression models assessed social and demographic risk factors for ADHD in children with and without CHD.
RESULTS: After multivariable correction, children with CHD had significantly higher prevalence of parent-reported ADHD than those without CHD (18.4% vs 10.7%, P < 0.05), with age-specific prevalence of 1.8% (ages 3-5), 13.1% (ages 6-8), 26.8% (ages 9-11), 25.5% (ages 12-14), and 25.0% (ages 15-17), with no significant differences across survey years. In weighted multivariable logistic regression, older age, male sex, prematurity, poorer parent-reported child health status, and foregone healthcare were associated with higher odds of ADHD in children with and without CHD (P < 0.05). Children with current CHD received treatment for ADHD with medication (44.5%) and behavioral intervention (46.2%) at similar prevalence to children without CHD (50.7% and 42.2%, respectively).
CONCLUSIONS: Children with CHD had higher parent-reported ADHD prevalence than peers without CHD, including nearly one in three adolescents aged 12-14. Children with CHD received ADHD treatments at prevalence comparable with those without CHD. Although limited by parent report and survey specificity, these national estimates highlight elevated ADHD prevalence in children with CHD and support strengthened neurodevelopmental surveillance guidelines.